Prestige Biopharma eyes complete value chain

BARCELONA, Spain – Prestige Biopharma, a Kospi-listed biopharmaceutical firm based in Singapore, said Tuesday it is seeking to complete its value chain of new drug development with its upcoming research center in Busan.
“Prestige Biopharma’s research and development of antibody drugs will pick up speed after the company opens its new research center in Busan,” Prestige Biopharma Chairman Park So-yeon told reporters at the Convention on Pharmaceutical Ingredients (CPHI) Worldwide 2023, the world’s largest pharma trade show that kicked off earlier this week in Barcelona, Spain.
The new plant, called Innovative Discovery Center or IDC, is currently under construction on a 31,000 square-meter site in the southern port city, with plans for completion by May next year. A total of $152 million has been injected into the construction.
With the completion, the firm’s main R&D unit will be relocated to the new facility. In line with the relocation, its staff members are also expected to surge from the current 55 to some 200 by 2030.
Currently, the firm’s Singapore headquarters is responsible for overseeing clinical trials and regulatory approval of new drugs, while its plant in Osong, North Chungcheong Province, is responsible for contract manufacturing.
Park stressed that the new Busan R&D center will play a key role in completing its value chain encompassing research, development and production of new antibody drugs.
She added the new facility will share floor space with its open innovation partners, including medical schools in the region.
"Open innovation will allow the company to speed up its research and development of new antibody drugs and reduce costs," Park said.
“When the new center is completed, we plan to invite officials from our partner firms, including the CancerX project. The center will become a global hub for new drug development.”
Cancer X is a public-private partnership program part of the Biden administration’s Cancer Moonshot Project. Prestige Biopharma also joined the program in July.
Currently, the company is waiting for regulatory approval for its biosimilars, including its Herceptin biosimilar HD201 and Humira biosimilar PBP1502. For the HD201, the firm has signed a license-out deal with four global partners.
相关文章
[KH explains] Hyundai to sell vehicles on Amazon in US sales push
Hyundai Motor Group’s cars will be sold online through Amazon for the first time in the US next year2023-11-29윤 대통령, 4박 6일 사우디·카타르 순방 마치고 귀국
윤석열 대통령이 26일 사우디아라비아와 카타르 국빈 방문을 마치고 귀국했다.윤 대통령은 이날 부인 김건희 여사와 대통령 전용기인 공군 1호기 편으로 성남 서울공항을 통해 입국했다.2023-11-29[KH Explains] A look back on Lee Jae
Friday is the first anniversary of Samsung Electronics Executive Chairman Lee Jae-yong's official as2023-11-29McDonald's Korea to increase prices of 13 items next week
McDonald's Korea said Thursday it will increase the price of 13 menu items by an average 3.7 pe2023-11-29尹, 과학기술자문회의와 오찬 “예타 간소화·예산집행 유연화 필요”
윤석열 대통령은 27일 연구개발(R&D) 예산 집행과 관련해 “적시에 연구가 지원될 수 있도록 예비타당성조사(예타)를 간소화하고 또 예산 집행을 유연하게 하며 연구에 필요한2023-11-29北, 러시아 외무장관 방북 발표…이달 18~19일 방문
세르게이 라브로프 러시아 외무부 장관이 지난 2021년 3월 23일 오후 인천국제공항을 통해 입국하고 있다. 연합뉴스북한이 세르게이 라브로프 러시아 외무장관의 방북 소식을 알렸다.2023-11-29
最新评论